NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01905631,"Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus",https://clinicaltrials.gov/study/NCT01905631,AUR0613,COMPLETED,"To demonstrate the ability of Aurstat to reduce pruritus in subjects with mild to moderate atopic dermatitis. Efficacy results will be based on subject assessment, IGA, and photographic evidence based on ordinal scales for tolerability.",YES,Pruritus|Atopic Dermatitis,DRUG: Aurstat Anti-Itch Hydrogel (Aurstat),"Reduction of Itching in AD, The ability of Aurstat to reduce itching in those diagnosed with Atopic Dermatitis aged 12-75 years of age.

Visual analog score (VAS assessment)- the VAS itch score was defined as the number of millimeters from the left side of a line (154 mm in length) that indicates their level of itching (0 mm (no itching)-154 mm (most itching))., 3-days",,,The Center for Clinical and Cosmetic Research,"Onset Dermatologics, Inc.",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",AUR0613,2013-07,2013-09,2013-09,2013-07-23,2022-07-15,2022-10-24,"Center for Clinical and Cosmetic Research, Aventura, Florida, 33180, United States",
